Kalaris Therapeutics (KLRS): Director received 18K units
Laurie Keating, Director at Kalaris Therapeutics, reported a grant / award of 18K units.
- 18K
- Derivative units
- Traded
- Aug 1, 2026
- Filed
- Aug 3, 2026
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Jul 3, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On July 3, 2026, Morana Jovan-Embiricos, Ph.D., notified Kalaris Therapeutics, Inc. (the “Company”) of her decision to resign as a member of the Company’s board of directors (the “Board”), effective immediately.”
- Jul 14, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On July 16, 2026, the Board of Directors (the “Board”) of Kalaris Therapeutics, Inc. (the “Company”) appointed Liisa Bayko as Chief Financial Officer and Treasurer of the Company, effective as of July 20, 2026 (the “Effective Date”).”
What came next
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Kalaris Therapeutics
For Kalaris Therapeutics, OQRO holds 1 fund holdings report (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its KLRS page.
How this filing works
Explore the data
Common questions
Which Kalaris Therapeutics (KLRS) insider traded, and how much?
Laurie Keating, Director at Kalaris Therapeutics, reported a grant / award of 18K units. Not an open-market trade.
When did it happen, and when was it made public?
Traded: Aug 1, 2026. Filed: Aug 3, 2026. That is 2 days between the two dates.
Is the dollar amount exact?
It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.
Where does this information come from?
From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Kalaris Therapeutics recently?
For Kalaris Therapeutics, OQRO holds 1 fund holdings report (13F) dated in the last 90 days. They are listed on the KLRS page.
Does this mean KLRS stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Kalaris Therapeutics
- SEC Schedule 13GOct 26, 2026
- SEC Form 4May 22, 2026
- SEC Form 4Mar 23, 2026
- SEC Form 4Feb 18, 2026
- SEC Form 4Mar 27, 2025
- SEC Form 4Feb 24, 2025
Everything OQRO holds on this company is on its KLRS page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
